Commitments and Contingencies (Details Textual) - USD ($)
|
|
|
|
1 Months Ended |
12 Months Ended |
|
|
|
|
|
|
May 02, 2016 |
Nov. 02, 2015 |
Oct. 08, 2015 |
Oct. 07, 2016 |
Aug. 19, 2016 |
May 31, 2016 |
Feb. 29, 2016 |
Oct. 19, 2015 |
Dec. 31, 2016 |
Jun. 30, 2016 |
Apr. 30, 2016 |
Jan. 31, 2016 |
Dec. 31, 2015 |
Oct. 31, 2015 |
Aug. 31, 2015 |
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Number of Securities Called by Warrants or Rights |
|
|
|
|
|
107,802
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
$ 7.50
|
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities |
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable |
|
|
|
|
|
750,000
|
|
|
|
|
|
|
|
|
|
Deferred Compensation Liability, Classified, Noncurrent |
|
|
|
|
|
|
|
|
$ 87,500
|
|
|
|
$ 0
|
|
|
Milestone Payment Description |
|
|
|
|
|
|
|
The amended milestone payments are as follows: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the first NDA within the United States - $500,000; and (iii) receipt of first marketing approval for sale of a license product in the United States - $600,000.
|
|
|
|
|
|
|
|
Mr. Louis [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Severance Costs |
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
Separation Agreement Description |
|
|
|
Pursuant to the Separation Agreement, Mr. Ploth will be permitted to exercise 25% of the options to purchase common stock granted to him in December 2015, or 50,000 shares, until May 2020.
|
|
|
|
|
|
|
|
|
|
|
|
Moleculin LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments for Other Fees |
|
|
|
|
|
306,186
|
|
|
|
|
|
|
|
|
|
Patent Law Firm [Member] | Minimum Fee and patent Expenses [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contractual Obligation, Total |
|
|
|
|
|
|
|
|
|
|
|
|
42,504
|
$ 65,504
|
|
Bonwick Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Letter Agreements Terms |
|
|
|
|
|
|
the Company agreed to: a) pay success fees equal to 7% of the gross proceeds from any form of financing; and b) issue five-year warrants to purchase 7% of the Companys equity securities sold with a cashless exercise provision, exercisable at 125% of the price per share of the Companys common stock paid by investors in the transaction. In addition, the Company agreed to reimburse Bonwick for all of its out-of-pocket expenses incurred in connection with the offering, not to exceed $25,000, and fees and expenses of their counsel not to exceed $100,000.
|
|
|
|
|
|
|
|
|
Success Fee Percentage |
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Percentage of Securities Called by Warrants or Rights |
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price Percentage Threshold |
|
|
|
|
|
|
125.00%
|
|
|
|
|
|
|
|
|
Payments for Underwriting Expense |
|
|
|
|
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
Bonwick Capital Partners LLC [Member] | IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reimburement of Expenses |
|
|
|
|
|
6,266
|
|
|
|
|
|
|
|
|
|
Payments of Stock Issuance Costs |
|
|
|
|
|
$ 646,872
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Number of Securities Called by Warrants or Rights |
|
|
|
|
|
107,802
|
|
|
|
|
|
|
|
|
|
Class of Warrant or Right, Exercise Price of Warrants or Rights |
|
|
|
|
|
$ 7.50
|
|
|
|
|
|
|
|
|
|
Bonwick Capital Partners LLC [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reimbursement Payable, Offering Costs |
|
|
|
|
|
|
25,000
|
|
|
|
|
|
|
|
|
Reimbursement Payable, Fees and Expenses of Counsel |
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
MD Anderson [Member] | Minimum Fee and patent Expenses [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contractual Obligation, Total |
|
|
$ 98,108
|
|
|
|
|
|
|
|
|
|
$ 45,000
|
98,108
|
|
MD Anderson [Member] | Minimum Annual Royalty [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contractual Obligation, Total |
|
|
65,504
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Officers' Compensation |
|
|
|
|
|
|
|
|
300,000
|
|
|
|
|
|
|
Deferred Compensation Liability, Classified, Noncurrent |
|
|
|
|
|
|
|
|
$ 87,500
|
$ 12,500
|
|
|
|
|
|
Chief Financial Officer and Executive Vice President [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Officers' Compensation |
|
|
|
|
$ 250,000
|
|
|
|
|
|
|
|
|
|
|
Deferred Compensation Arrangement with Individual, Maximum Contractual Term |
|
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
Chief Financial Officer and Executive Vice President [Member] | Employee Stock Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred Compensation Arrangement with Individual, Shares Issued |
|
|
|
|
400,000
|
|
|
|
|
|
|
|
|
|
|
Deferred Compensation Arrangement with Individual, Exercise Price |
|
|
|
|
$ 5.85
|
|
|
|
|
|
|
|
|
|
|
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period |
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
Patent and Technology License Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contractual Obligation, Total |
|
|
|
|
|
|
|
|
|
|
$ 91,186
|
$ 175,000
|
|
$ 125,000
|
|
Payments for Royalties |
|
$ 125,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
License Agreement, Maintenance Fee |
$ 20,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
License Agreement, Maintenance Fee Annual Increase |
10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments for Other Fees |
|
|
300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
License Agreement, Maintenance Fee - Maximum Payable Per Year |
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Patent and Technology License Agreement [Member] | Servicing Fee payable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contractual Obligation, Due First Anniversary April 2, 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000
|
Contractual Obligation, Due Second Anniversary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000
|
Contractual Obligation, Due Third Anniversary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
Contractual Obligation, Due Fourth Anniversary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60,000
|
Contractual Obligation, Due Fifth Anniversary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,000
|
Contractual Obligation, Due Sixth Anniversary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
Patent and Technology License Agreement [Member] | Minimum Annual Royalty [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contractual Obligation, Due in Next Fiscal Year, After Product Approval |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
Contractual Obligation, Due in Second Year, After Product Approval |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
400,000
|
Contractual Obligation, Due in Third Year, After Product Approval |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 600,000
|
Patent and Technology License Agreement [Member] | Letter Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments for Other Fees |
|
|
$ 691,186
|
|
|
|
|
|
|
|
|
|
|
|
|